Insulin lispro protamine biosimilar(25R) (Wanbang Pharma)

精蛋白锌赖脯胰岛素生物类似药(25R)(万邦生化)

Report date: 2026/04/01 11:28:26

Base Information

Drug NameInsulin lispro protamine biosimilar(25R) (Wanbang Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A